CAR T-cell Therapy in Patients With Renal Dysfunction

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
• Adequate bone marrow function to receive lymphodepleting chemotherapy
• Renal function </= 60mL/min/1.73m2
• ECOG 0-2

You cannot join if

• Relative CNS disorders
• Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
• Use of therapeutic dose systemic corticosteroids (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

fludarabine phosphate. The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. NCI Drug Dictionary

CAF regimen. A regimen consisting of oral cyclophosphamide, doxorubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer. NCI Drug Dictionary

Treatments listed in the registry

• Fludarabine (Drug): Received IV on Days -5 to -3 before CAR T cell therapy
• Cyclophosphamide (Drug): Received IV on Days -5 to -3 before CAR T cell therapy

Non Randomized · Single Group · masking: None

Main goals

• Occurrence of CRS (90 days)
• Occurrence of ICANS (90 days)
• Occurrence of Cytopenias (90 days)

Planned enrollment: 20 (estimated).

• Caitlin Guzowski, Atlanta, Georgia

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT05909059
• NCI Drug Dictionary: C1102
• NCI Drug Dictionary: C405

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Oct 13, 2026. Public record; not medical advice.